303 related articles for article (PubMed ID: 33622569)
1. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
El-Ghazzi N; Lavaud P
Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
[No Abstract] [Full Text] [Related]
2. Nivolumab plus ipilimumab for the first-line treatment of metastatic NSCLC.
Rijavec E; Indini A; Ghidini M; Tomasello G; Cattaneo M; Barbin F; Grossi F
Expert Rev Anticancer Ther; 2021 Jul; 21(7):705-713. PubMed ID: 33719827
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
4. First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Ackermann CJ; Adderley H; Ortega-Franco A; Khan A; Reck M; Califano R
Drugs; 2020 Nov; 80(17):1783-1797. PubMed ID: 32986224
[TBL] [Abstract][Full Text] [Related]
5. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
6. Nivolumab plus ipilimumab in non-small-cell lung cancer.
Reck M; Borghaei H; O'Byrne KJ
Future Oncol; 2019 Jul; 15(19):2287-2302. PubMed ID: 31066582
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC.
Li J; Zhang T; Xu Y; Lu P; Zhu J; Liang W; Jiang J
Immunotherapy; 2020 Oct; 12(14):1067-1075. PubMed ID: 32811247
[No Abstract] [Full Text] [Related]
8. Immunotherapy combinations in advanced nonsmall cell lung cancer.
Pirker R
Curr Opin Oncol; 2021 Jan; 33(1):73-79. PubMed ID: 33186185
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for the treatment of small cell lung cancer.
Simeone E; Grimaldi AM; Festino L; Trojaniello C; Vitale MG; Vanella V; Curvietto M; Ascierto PA
Expert Rev Respir Med; 2020 Jan; 14(1):5-13. PubMed ID: 31622114
[No Abstract] [Full Text] [Related]
11. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
Bestvina CM; Pointer KB; Karrison T; Al-Hallaq H; Hoffman PC; Jelinek MJ; Juloori A; Melotek JM; Murgu S; Partouche J; Vokes EE; Weichselbaum RR; Pitroda SP; Patel JD; Chmura SJ
J Thorac Oncol; 2022 Jan; 17(1):130-140. PubMed ID: 34500113
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC.
Kahl KL
Oncology (Williston Park); 2020 Jul; 34(7):254. PubMed ID: 32674209
[TBL] [Abstract][Full Text] [Related]
13. Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
Li Z; Lu S
J Clin Oncol; 2023 Feb; 41(6):1172-1175. PubMed ID: 36623229
[No Abstract] [Full Text] [Related]
14. Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer.
Uprety D
Clin Lung Cancer; 2019 Mar; 20(2):63-65. PubMed ID: 30545572
[No Abstract] [Full Text] [Related]
15. Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer.
Cope S; Keeping ST; Goldgrub R; Ayers D; Jansen JP; Penrod JR; Korytowsky B; Juarez-Garcia A; Yuan Y
J Comp Eff Res; 2019 Jul; 8(10):733-751. PubMed ID: 31237143
[No Abstract] [Full Text] [Related]
16. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors.
Kelleher T; Cai J; Botwood NA; Labriola DF
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558277
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
[TBL] [Abstract][Full Text] [Related]
18. [First line durvalumab and tremelimumab in combination with chemotherapy for non-oncogene addicted metastatic non-small cell lung cancer (NSCLC)].
Porte M; Pierret T
Bull Cancer; 2023 Nov; 110(11):1094-1096. PubMed ID: 37758567
[No Abstract] [Full Text] [Related]
19. Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
Xiao G; Liu Z; Gao X; Wang H; Peng H; Li J; Yang L; Duan H; Zhou R
Immunotherapy; 2021 Aug; 13(12):1031-1051. PubMed ID: 34231370
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]